Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies

• Published in: Journal of Nuclear Medicine Vol. 53; no. 6; pp. 922 - 927
• Main Authors: Erba, Paola A, Sollini, Martina, Orciuolo, Enrico, Traino, Claudio, Petrini, Mario, Paganelli, Giovanni, Bombardieri, Emilio, Grana, Chiara, Giovannoni, Leonardo, Neri, Dario, Menssen, Hans D, Mariani, Giuliano
• Format: Journal Article
• Language: English
• Published: United States Society of Nuclear Medicine 01-06-2012
• Subjects: Adolescent; Adult; Aged; Cancer; Chemotherapy; Clinical Trials as Topic; Compassionate Use Trials; Female; Fibronectins - metabolism; Humans; Iodine Radioisotopes - therapeutic use; Lymphoma; Lymphoma, Non-Hodgkin - radiotherapy; Male; Middle Aged; Multiple Myeloma - radiotherapy; Radioimmunotherapy - adverse effects; Recurrence
• ISSN: 0161-5505; 1535-5667; 2159-662X
• DOI: 10.2967/jnumed.111.101006

We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab.
Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple myeloma patients.
In 14 of 18 patients, selective tumor uptake was found; 11 of 15 lymphoma patients, including 9 of 11 with Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria-based target-to-bone marrow ratio > 10:1 for EudraCT no. 2005-000545 or > 4:1 for EudraCT no. 2007-007241-12 at dosimetric imaging). Two HL and 1 diffuse large B cell lymphoma patient achieved complete response; 1 HL patient had partial response. Both multiple myeloma patients receiving R-RIT experienced stabilization of disease. Therefore, the overall objective response rate was 40%. Uncomplicated grade 3-4 thrombocytopenia or leukocytopenia was observed in 5 R-RIT patients, lasting 4-129 d.
R-RIT showed a favorable benefit and risk profile in advanced relapsed lymphoma patients and induced complete response in 2 heavily pretreated, relapsed HL patients and in 1 diffuse large B cell lymphoma patient. These results warrant further exploration of R-RIT in larger phase II clinical trials.